Neuropharmacology represents one of the therapeutic areas with the greatest number of molecules in development, reflecting research advances in the understanding of the basis of the diseases useful for developing potentially innovative interventions. However, neuropsychiatric conditions historically have been among the most difficult for which to develop effective and safe new therapies, due to the complexity of physiopathology and clinical presentation; therefore, curative treatments for important diseases, such as neurodegenerative diseases, are still lacking. Recognizing a true innovation can accelerate the development and adoption of valuable treatment options for neuropsychiatric disorders, encouraging their prioritization to make them quickly available for patients with high unmet (or inadequately met) medical needs.
This Research Topic will collect updated evidence about innovation for neuropsychiatric unmet medical needs, characterized by a major impact on the life expectancy and the quality of life of patients but also on the healthcare system and the society. In particular, it will be focused on the current state and future perspectives in the area of innovation in neuropsychopharmacology, including treatments that have already been demonstrated to generate significant improvements in clinical outcomes previously unattainable; furthermore, updates on experimental products which would potentially represent disease-modifying therapies are welcomed. For instance, manuscripts focused on advanced therapy medicinal products (ATMPs) are expected; indeed, ATMPs are changing the landscape of therapy for neuromuscular disorders aiming to potentially provide great and sustained benefits. As regards products already on the market, evidence from real-world data will be acceptable, including commentaries about access to innovation.
The Topic welcomes submissions of Original Research, Reviews, Clinical trials, perspectives, Policy Brief, and Opinion articles that cover the following topics but are not limited to:
• real-world data related to the use of products for neuropsychiatric diseases recognized as real innovation already available in clinical practice;
• access to innovation in specific national contexts (reimbursement, risk-sharing agreements, cost);
• investigation of potential innovative pharmacological treatments for unmet medical needs (e.g. neurodegenerative disorders, schizophrenia, treatment-resistant depression).
Neuropharmacology represents one of the therapeutic areas with the greatest number of molecules in development, reflecting research advances in the understanding of the basis of the diseases useful for developing potentially innovative interventions. However, neuropsychiatric conditions historically have been among the most difficult for which to develop effective and safe new therapies, due to the complexity of physiopathology and clinical presentation; therefore, curative treatments for important diseases, such as neurodegenerative diseases, are still lacking. Recognizing a true innovation can accelerate the development and adoption of valuable treatment options for neuropsychiatric disorders, encouraging their prioritization to make them quickly available for patients with high unmet (or inadequately met) medical needs.
This Research Topic will collect updated evidence about innovation for neuropsychiatric unmet medical needs, characterized by a major impact on the life expectancy and the quality of life of patients but also on the healthcare system and the society. In particular, it will be focused on the current state and future perspectives in the area of innovation in neuropsychopharmacology, including treatments that have already been demonstrated to generate significant improvements in clinical outcomes previously unattainable; furthermore, updates on experimental products which would potentially represent disease-modifying therapies are welcomed. For instance, manuscripts focused on advanced therapy medicinal products (ATMPs) are expected; indeed, ATMPs are changing the landscape of therapy for neuromuscular disorders aiming to potentially provide great and sustained benefits. As regards products already on the market, evidence from real-world data will be acceptable, including commentaries about access to innovation.
The Topic welcomes submissions of Original Research, Reviews, Clinical trials, perspectives, Policy Brief, and Opinion articles that cover the following topics but are not limited to:
• real-world data related to the use of products for neuropsychiatric diseases recognized as real innovation already available in clinical practice;
• access to innovation in specific national contexts (reimbursement, risk-sharing agreements, cost);
• investigation of potential innovative pharmacological treatments for unmet medical needs (e.g. neurodegenerative disorders, schizophrenia, treatment-resistant depression).
